Imiquimod (Q73415890)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Imiquimod (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

Robert B Skinner

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 April 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

291-300

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

Imiquimod 5% cream (Aldara).

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Immunomodulating and antiviral activities of the imidazoquinoline S-28463.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Cytokine Induction in Hairless Mouse and Rat Skin After Topical Application of the Immune Response Modifiers Imiquimod and S-28463

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Cytokine induction in mice by the immunomodulator imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Imiquimod: an immune response modifier

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Efficacy of S26308 against guinea pig cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Interleukin-12 and its role in the generation of TH1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Toll receptors and sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of genital warts with an immune-response modifier (imiquimod)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts--results of an open-label, multicentre Phase IIIB trial

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Difficult wart cases -- use of imiquimod cream 5%.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Successful treatment of extensive condyloma acuminata of the inguinal area and thigh with topical imiquimod cream

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

The importance of patient and healthcare provider perceptions in the evaluation of imiquimod and other prior treatments for anogenital warts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

New patient-applied therapy for anogenital warts is rated favourably by patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Granuloma annulare resolved with topical application of imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Lip papillomatosis in immunodeficiency: therapy with imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Imiquimod therapy for molluscum contagiosum

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of Molluscum Contagiosum in Males with an Analog of Imiquimod 1% in Cream: A Placebo‐Controlled, Double‐Blind Study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Treatment of molluscum contagiosum with topical 5% imiquimod cream

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Attenuation of virus-induced airway dysfunction in rats treated with imiquimod

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2802%2900094-3

7 January 2021

10.1016/S0733-8635(02)00094-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12757252%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference